X

Drug Profile

Research programme: NADPH oxidase 2 gene therapies - immunoVec

Latest Information Update: 04 May 2021

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator immunoVec
Class Gene therapies
Mechanism of Action Gene transference; NADPH oxidase 2 replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Chronic granulomatous disease
New Molecular Entity No

Highest Development Phases

Preclinical Chronic granulomatous disease

Most Recent Events

07 Apr 2021 Preclinical studies in Chronic granulomatous disease in USA (Parenteral) before April 2021
07 Apr 2021 NADPH oxidase 2 gene therapy receives Orphan Drug status for Chronic granulomatous disease in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com